title: Reply to L. Gianni et al.
authors.affiliation: Herbert Irving Comprehensive Cancer Center, Columbia University, and New York Presbyterian Hospital, New York, NY dlh23@cumc.columbia.edu.
authors.forename: Dawn L
authors.initials: DL
authors.lastname: Hershman
authors.affiliation: SWOG Statistical Center and Fred Hutchinson Cancer Research Center, Seattle, WA.
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Unger
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D047072:Aromatase Inhibitors / Q000009:adverse effects*; D018771:Arthralgia / Q000188:drug therapy*; D001943:Breast Neoplasms / Q000188:drug therapy*; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D059352:Musculoskeletal Pain / Q000188:drug therapy*; D009141:Musculoskeletal System / Q000503:physiopathology*
chemical_list: D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D015525:Fatty Acids, Omega-3